SARS-CoV-2 Infection and Risk Management in Multiple Sclerosis
Amado Diaz de la Fe,
Alejandro Armando Peláez Suárez,
Marinet Fuentes Campos,
Maivis Noemí Cabrera Hernández,
Carlos-Alberto Goncalves,
Stephen Schultz,
Dario Siniscalco,
Maria Angeles Robinson-Agramonte
Affiliations
Amado Diaz de la Fe
Neuromuscular Diseases Clinic, International Center for Neurological Restoration, Habana 11300, Cuba
Alejandro Armando Peláez Suárez
Neuromuscular Diseases Clinic, International Center for Neurological Restoration, Habana 11300, Cuba
Marinet Fuentes Campos
Departamento de Medicina Familiar y Comunitaria Policlínico 28 de Enero, Habana 11300, Cuba
Maivis Noemí Cabrera Hernández
Consulta de Alergia, Hospital General Secretaria de Salud, Iguala City 40000, Mexico
Carlos-Alberto Goncalves
Department of Biochemistry, Federal University of Rio Grande do Sul, Porto Alegre 90040-060, Brazil
Stephen Schultz
Department of Cellular and Integrative Physiology, Center for Biomedical Neuroscience, University of Texas (UT) Health Science Center San Antonio, San Antonio, TX 78229, USA
Dario Siniscalco
Department of Experimental Medicine, University of Campania, 80138 Naples, Italy
Maria Angeles Robinson-Agramonte
Neuroimmunology Department, Research Center, International Center for Neurological Restoration, Habana 11300, Cuba
The novel coronavirus can cause a severe respiratory disease with impact on the central nervous system, as has been reported by several medical health services. In the COVID-19 pandemic caused by the SARS-CoV-2 neurotrophic virus, neurologists have focused their attention on the early identification of suggestive manifestations of the neurological impact of the disease. In this context, they are exploring related chronic disease and the possibility of achieving a more effective understanding of symptoms derived from COVID-19 infection and those derived from the course of preexisting neurological disease. The present review summarizes evidence from the infection with SARS-CoV-2 and the management of the risks of multiple sclerosis and how it is related to the risks of general comorbidities associated with COVID-19. In addition, we reviewed other factors characteristic of MS, such as relapses, and the maximum tolerated dose of treatment medications from clinical and experimental evidence.
